Venetoclax and Lintuzumab-Ac225 in AML Patients
Clinical trial NCT03867682 · UNKNOWN
Trial details
- NCT number
- NCT03867682
- Sponsor
- Actinium Pharmaceuticals
- Status
- UNKNOWN
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2020-01-15
- Primary completion
- 2023-11-01
- Enrollment
- 38
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.